Related Experiment Videos
Prophylactic chemolipiodolization for postoperative hepatoma patients
1Department of Surgery II, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0192, Japan. Shimoda9@ms.toyama-mpu.ac.jp
Hepato-Gastroenterology
|May 31, 2001
Summary
Prophylactic chemolipiodolization after liver surgery significantly reduced intrahepatic recurrence and improved survival rates in hepatocellular carcinoma patients. This treatment offers a promising strategy for better patient outcomes.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Medical Oncology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer.
- Hepatic resection is a common treatment for HCC.
- Intrahepatic recurrence is a significant challenge after HCC resection.
Purpose of the Study:
- To evaluate the efficacy of prophylactic chemolipiodolization following hepatic resection in HCC patients.
- To assess the impact of this treatment on intrahepatic recurrence and patient survival.
Main Methods:
- Retrospective analysis of 44 HCC patients who underwent hepatectomy.
- Two groups: prophylactic chemolipiodolization (Group A, n=21) vs. no prophylactic treatment (Group B, n=23).
- Comparison of clinicopathological background, recurrence rates, and survival outcomes.
Main Results:
- No significant differences in clinicopathological background between groups.
- Significantly lower rates of multiple intrahepatic recurrence in Group A (P < 0.02).
- Group A showed significantly higher recurrence-free survival (3-yr: 54.4% vs 15.7%; 5-yr: 31.1% vs 7.9%) and overall survival (3-yr: 95.2% vs 40.1%; 5-yr: 80.4% vs 22.9%).
Conclusions:
- Postoperative prophylactic chemolipiodolization is effective in reducing intrahepatic recurrence in HCC patients.
- This treatment strategy may prolong survival for patients undergoing hepatic resection for HCC.